Bluebird Bio Stock News

Today's losers are selling for peanuts, and they just might become tomorrow's winners.

Today's losers are selling for peanuts, and they just might become tomorrow's winners.

Bluebird (BLUE) delivered earnings and revenue surprises of 0% and 79.84%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

bluebird bio (BLUE) saw its Q4 2021 net loss narrow ~22% as it posted product revenue for the first time.

CAMBRIDGE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (NASDAQ: BLUE) (“bluebird bio” or the “Company”) today reported financial results and business highlights for the fourth quarter and full year ended December 31, 2021, shared recent operational progress, and provided a corporate update. “2022 is set up to be a landmark year for bluebird bio, with LVV gene therapies for β-thalassemia and cerebral adrenoleukodystrophy under review by the U.S. Food and Drug Administration (FDA) and plans to sub

Bluebird (BLUE) delivered earnings and revenue surprises of 0% and 79.84%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

These companies have taken a beating, and there's no relief on the horizon.

Apellis Pharmaceuticals, Inc. (APLS) delivered earnings and revenue surprises of -21.97% and 607.46%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead fo

The FDA accepts Bristol Myers' (BMY) sBLA for Breyanzi under a priority review as a second-line treatment for relapsed/refractory large B-cell lymphoma. A decision is due on Jun 24, 2022.

Bluebird (BLUE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Bluebird (BLUE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

bluebird bio Inc. (NASDAQ:BLUE)s traded shares stood at 3.51 million during the last session, with the companys beta value hitting 1.60. At the close of trading, the stocks price was $6.91, to imply a decrease of -6.11% or -$0.45 in intraday trading. The BLUE shares 52-week high remains $30.55, putting it -342.11% down since that bluebird bio Inc. (NASDAQ: BLUE) Dropped -43.31% In 6 Months Heres What Might Happen Next Read More »

Bluebird Bio is nearing approval of three potentially curative treatments for severe genetic diseases, although approval has been continually delayed. They recently left Europe over pricing disagreeme